Key Points
- BeOne Medicines SVP Chan Henry Lee sold 1,115 shares for about $446,914 at an average price of $400.82 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 71% to 455 shares.
- The company reported quarterly EPS of $3.64, beating the $2.34 consensus, and revenue of $1.89 billion versus expectations of $1.76 billion.
- Analyst sentiment is broadly positive: 16 analysts rate the stock Buy and one rates it Hold, with a consensus “Moderate Buy” rating and a $436.92 target price.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Lee sold 1,115 shares of the firm's stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $400.82, for a total transaction of $446,914.30. Following the sale, the senior vice president owned 455 shares of the company's stock, valued at $182,373.10. This trade represents a 71.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, September 30th, Chan Lee sold 1,115 shares of BeOne Medicines stock. The stock was sold at an average price of $375.00, for a total value of $418,125.00.
- On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The shares were sold at an average price of $360.00, for a total value of $959,760.00.
BeOne Medicines Price Performance
Shares of NASDAQ ONC opened at $417.33 on Tuesday. The firm has a market cap of $45.82 billion, a P/E ratio of 66.51 and a beta of 0.63. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $420.00. The business's 50 day moving average is $364.50 and its 200-day moving average is $326.72.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, topping the consensus estimate of $2.34 by $1.30. The business had revenue of $1.89 billion during the quarter, compared to analysts' expectations of $1.76 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 8.99 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ONC. Wolfe Research reissued an "outperform" rating and set a $370.00 target price on shares of BeOne Medicines in a report on Monday, August 10th. Truist Financial reissued a "buy" rating and issued a $448.00 target price (up from $420.00) on shares of BeOne Medicines in a research report on Friday. Wall Street Zen upgraded shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 18th. Weiss Ratings raised shares of BeOne Medicines from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Finally, Royal Bank Of Canada raised their price target on shares of BeOne Medicines from $459.00 to $465.00 and gave the stock an "outperform" rating in a research report on Friday. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $436.92.
View Our Latest Research Report on ONC
Institutional Investors Weigh In On BeOne Medicines
Several institutional investors have recently made changes to their positions in ONC. Bank of America Corp DE boosted its stake in shares of BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company's stock valued at $120,354,000 after buying an additional 26,441 shares during the period. Baird Financial Group Inc. grew its position in BeOne Medicines by 5.5% during the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company's stock worth $105,148,000 after buying an additional 19,327 shares in the last quarter. First Trust Advisors LP increased its stake in BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company's stock worth $71,696,000 after acquiring an additional 115,601 shares during the period. Jennison Associates LLC increased its stake in BeOne Medicines by 102.1% during the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company's stock worth $45,871,000 after acquiring an additional 78,027 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in BeOne Medicines by 96.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 110,586 shares of the company's stock worth $32,841,000 after acquiring an additional 54,260 shares during the period. 48.55% of the stock is currently owned by institutional investors.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.
Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
